DRKS00026081尚未招募不适用
PRognosis Evaluation using in-Depth immune phenotyping and metagenomic analysis In Colorectal cancer Therapy - PREDICT
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •Adult patients
- •Patients capable of giving informed consent
- •Presence of a valid declaration of informed consent
- •Presence of a valid declaration of informed consent for participation in biobanking
- •Patients with colorectal carcinoma or screening colonoscopy (control group)
排除标准
- •age younger than 18 years
- •no informed consent for participation of biobanking
研究者
相似试验
已完成
不适用
Evaluation of the immune-profiling for patients participating in Phase Ib/II Study of BBI608 in Combination with Pembrolizumab and the relationship between the immune-profiling and efficacy using paired biopsies and peripheral blood.metastatic colorectal cancerJPRN-UMIN000024500ational Cancer Center Hospital East59
尚未招募
不适用
Investigation of biomarkers to predict immune-related adverse events in patients with non-small cell lung canceron-small cell lung cancerJPRN-UMIN000047162Kobe University114
进行中（未招募）
1 期
A prospective study to evaluate the immune response of UK infants receiving the 13-valent pneumococcal conjugate vaccine as part of their routine primary immunisation schedule at 2 and 4 months (code: P13UK) - P13UKPrevenar13 was introduced into the national childhood immunisation programme to prevent serious bacterial infections caused by the germ Streptococcus pneumonia, including meningitis, septicaemia and pneumonia.EUCTR2010-023865-22-GBHealth Protection Agency
已完成
4 期
Responses to booster vaccinations in UK toddlersISRCTN84763401Health Protection Agency (UK)200
招募中
不适用
Prediction of immune related adverse events by genetic analysismalignant melanoma, lung cancer, renal cancer, Hodgkin lymphomaJPRN-UMIN000026047Yokohama City University Hospital300